معرفی
Dr. Mark Morris is a Reader in Molecular Oncology at the School of Biology, Chemistry and Forensic Science, Faculty of Science and Engineering, University of Wolverhampton. He leads a research group within the Research Institute in Healthcare Science (RHIS), focusing on the molecular genetics of cancer development.
Education:
- PhD in Molecular Biology, University of Wales College of Medicine (2001)
Research Interests: Dr. Morris investigates epigenetic gene dysregulation in tumour formation and metastasis, particularly DNA methylation and microRNAs in childhood brain and kidney cancers. His work also explores RNA-processing in tumours and the identification of new cancer therapeutics. His research spans molecular oncology, epigenetics, cancer genetics, and targeted therapy development.
Publication Trends: His recent publications focus on epigenetic mechanisms in renal cell carcinoma and glioblastoma, with an emphasis on methylation profiling, tumour suppressor gene silencing, and genetic predisposition syndromes. His work frequently appears in high-impact journals in oncology and genetics.
Scientific Contributions:
- Key researcher in identifying germline mutations in DIS3L2 linked to Perlman syndrome and Wilms tumor.
- Contributed to the discovery of novel tumour suppressor genes in renal cancer through methylation studies.
- Active collaborator with leading institutions including the University of Cambridge and University of Birmingham.
Teaching and Mentorship: Dr. Morris teaches biochemistry, cell biology, and molecular genetics with applications to human disease. He supervises research students and welcomes PhD candidates interested in cancer genetics, epigenetics, and RNA biology. He previously held a research position at the University of Birmingham, where he currently holds an Honorary Lecturer title.
Research Environment: Dr. Morris works within a multidisciplinary team at RHIS and collaborates with clinical researchers across the UK, including at Lancashire Teaching Hospitals and the Walton Centre for Neurology and Neurosurgery. His future projects include studying exosome-mediated RNA dysregulation and targeted DNA demethylation as cancer therapy.
.png)
